SLC5A2 and type 2 diabetes mellitus: Based on the detailed discussion described above, we conclude that SGLT2 inhibitors are able to reduce oxidative stress in T2DM by upregulating antioxidant proteins, downregulating pro-oxidant enzymes, reducing AGE-RAGE interactions, improving mitochondrial function, reducing proinflammatory cytokines and inhibiting the intrarenal RAS.